2023-508234-34-00招募中2 期
A phase 2b, multicenter, double-blind, placebo-controlled, study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of obefazimod in subjects with moderately to severely active Crohn’s disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Abivax
- 入组人数
- 161
- 试验地点
- 107
- 主要终点
- For induction and maintenance phase: change from baseline in CDAI score at Week 12 and Week 52.
研究概览
简要总结
For Induction and Maintenance phase: to evaluate the efficacy of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. For Extension Phase: to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female (at birth) 18 to 75 years old.
- •Subjects must understand, sign and date the written voluntary informed consent form and be able and willing to comply with study visits and procedures as per protocol.
- •Confirmed and documented diagnosis of CD based on endoscopy and histology reports. For subjects with no documented diagnosis, the diagnosis must be confirmed at the screening on the local endoscopy and histology reports (with local biopsies).
- •Moderately to severely active CD as defined by 220 ≤ CDAI ≤
- •and SES-CD ≥ 6 for ileocolonic or colonic disease or SES-CD ≥ 4 for isolated ileal disease (per central reading).
- •Documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressants, biologic or biosimilar therapies, janus kinase inhibitors and/or new drugs approved for the treatment of CD during the study (note: failure to only 5- ASA is not accepted).
- •Women of childbearing potential (WOCBP) subjects and male subjects with WOCBP partner must agree to comply with contraception requirements as stated in this protocol.
- •Subject should be affiliated to a health insurance policy whenever required by a participating country or state.
排除标准
- •WOCBP subject who is pregnant or breast-feeding at screening, or intends to become pregnant during the study; or male subject with WOCBP partner who intends to be pregnant during the study.
- •Serious illness requiring hospitalization (not related to CD) within 4 weeks prior to screening.
- •Subject with certain infectious conditions (please see protocol for details).
- •Subject with uncontrolled ischemic heart disease and/or a history of congestive heart failure with New York Heart Association (NYHA) class 3 or 4 symptoms.
- •Subject with a known family or personal history of congenital or acquired long QT syndrome, or subjects with a marked baseline prolongation of QT/ heart-rate-corrected QT (QTc) interval (eg, repeated demonstration of a QTc interval [Fridericia correction] > 450 milliseconds [msec] for male and > 460 msec for female).
- •Subject with a history of torsade de pointe (TdP).
- •Acute or chronic clinically relevant pulmonary, hepatic, or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, or any other clinically significant medical problems as determined by physical examination, laboratory screening tests, and/or medical history (note: treated autoimmune hypothyroidism and autoimmune diabetes are allowed).
- •Subjects who received live vaccine within 3 months prior to screening and/or subject who is planning to receive such a vaccine during the study duration.
- •Subject with the following hematological and biochemical laboratory parameters obtained during the screening period: a. Hemoglobin ≤ 8.0 g/dL. b. Absolute neutrophil count < 750/mm3 . c. Platelets < 100,000 /mm3 d. eGFR < 60 mL/min/1.73 m2 e. Total serum bilirubin > 1.5 x ULN (except if related to pre-existing and documented Gilbert syndrome) f. Aspartate aminotransferase and/or alanine aminotransferase > 2 x ULN.
- •Subject who does not meet the washout period requirements prior to the screening endoscopy as described in the prohibited medication section of the study protocol.
- •Use of any investigational or nonregistered product within 5 half lives preceding baseline and during the study.
- •Current diagnosis of ulcerative colitis or indeterminate colitis.
- •Subjects previously treated with obefazimod.
- •subjects with a known hypersensitivity to the active substance or to any of the excipients.
- •Illicit drug or alcohol abuse or dependence.
- •Subject who is committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
- •Any condition, which in the opinion of the investigator, could compromise the subject’s safety or adherence to the study protocol.
- •CD without ileal and/or colonic involvement.
- •Untreated active external or perianal fistula or abscess. Stable fistula without abscess and with minimal or low drainage may be enrolled.
- •Symptomatic bowel stricture and/or stenosis not passable in endoscopy (including pediatric endoscope).
- •Certain situations related to CD surgery (see protocol for details).
- •Certain situations related to CD treatments (see protocol for details).
- •History of colonic cancer or colonic low grade or high-grade dysplasia adenomatous polyps, and/or at the screening endoscopy, evidence of low grade or high grade dysplasia adenomatous polyps (fully removed or not).
- •Subject with history of, or diagnosed with, the following during screening: primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cirrhosis.
结局指标
主要结局
For induction and maintenance phase: change from baseline in CDAI score at Week 12 and Week 52.
For induction and maintenance phase: change from baseline in CDAI score at Week 12 and Week 52.
次要结局
- For Induction and Maintenance phase: (efficacy) Change from baseline in SES-CD at Week 12 and at Week 52 respectively.
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with endoscopic response at Week 12 and at Week 52 respectively.
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with no SES-CD ulcer subscore > 1 in at least one segment at Week 12 and at Week 52 respectively.
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with CDAI clinical remission at Week 12 and at Week 52 respectively.
- For Maintenance phase: (efficacy) Proportion of subjects with sustained CDAI clinical remission at Week 52.
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with PRO-2 clinical remission at Week 12 and at Week 52 respectively.
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with CDAI clinical response at Week 12 and at Week 52 respectively.
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with PRO-2 clinical response at Week 12 and at Week 52 respectively
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with CDAI clinical response and endoscopic response at Week 12 and at Week 52 respectively
- For Induction phase and Maintenance phase: (efficacy) Proportion of subjects with endoscopic remission at Week 12 and at Week 52 respectively
- For Induction phase, Maintenance and Extension phase: Safety Incidence of all treatment-emergent adverse events (TEAEs), causally related TEAEs, all serious adverse events (SAE) and causally related SAEs.
- For Induction, Maintenance and Extension phase: Safety, Incidence of AEs leading to discontinuation
- For Induction, Maintenance and Extension phase: (safety) incidence of adverse events of special interest (AESIs)
- For Induction, Maintenance and Extension phase: (safety) Incidence and severity of laboratory abnormalities and change from baseline in laboratory values
- For Induction, Maintenance and Extension phase: PK, Obefazimod and ABX464-N-Glu plasma concentrations at baseline and at specified timepoints during Induction, Maintenance and Extension and PK parameters as determined by population PK analysis
研究者
Clinical Operations
Scientific
Abivax
研究点 (107)
Loading locations...
相似试验
招募中
3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Subjects with Moderate-to-Severe Plaque PsoriasisPlaque psoriasis2024-519919-34-00Can-Fite Biopharma Ltd.248
招募中
2 期
A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer2023-503356-27-00Inspirna Inc., Inspirna Inc.86
招募中
3 期
A treatment study in patients with WHIM Syndrome.2024-518461-10-00X4 Pharmaceuticals Inc.6
进行中（未招募）
3 期
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisNCT07291284Longbio Pharma546
招募中
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT07284459Contineum Therapeutics324